Compare Cassava Sciences Inc (FLNA) vs Levi Strauss & Co. (LEVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Levi Strauss & Co. — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Levi Strauss & Co. trades at $19.01 (market cap $7.51B). The key difference: Levi Strauss & Co. is far larger — about 190.6× Cassava Sciences Inc's market cap, and Levi Strauss & Co. pays a 3.28% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Levi Strauss & Co. for 70 Days on average.
| FLNA | LEVI | |
|---|---|---|
Market Cap | $39.40M | $7.51B |
Volume | 759,018 | 17,462,954 |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $25.53 |
52-Week Low | $0.68 | $17.92 |
Typical Hold Time | 37 Days | 70 Days |
Enterprise Value | -$43.28M | $9.06B |
Dividend Yield | — | 3.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 7.01% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam for epilepsy research provides a positive catalyst, with patient screening expected by Q1 2027.
Despite operational losses and negative cash flow, analyst consensus is bullish with 8 buy ratings versus 4 hold. The key investment opportunity lies in the clinical progress of simufilam, while risks include sustained cash burn and reliance on successful drug development outcomes in a competitive biotech landscape.
Levi Strauss (LEVI) trades at $19.05, down 7.21% over 24 hours, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 12.84, robust profitability margins, and consistent earnings beats in recent quarters. Recent news highlights a '90s fashion revival benefiting the brand and the appointment of a new CFO effective November 2026. Cash flow trends have improved, with net cash flow turning positive in 2025 after prior volatility.
The outlook is positive given analyst consensus of a $27.80 price target and 79% buy ratings, though near-term price weakness and competitive pressures in apparel present risks. Earnings growth and direct-to-consumer expansion are key catalysts, but investors face execution risks and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →
